相关临床试验
11
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1885
已完成
7
63.6%
尚未招募
1
9.1%
招募中
3
27.3%
暂无批准数据
- A digital twin of the left atrium, created by merging CT images with electroanatomical mapping data, can simulate the effects of amiodarone (AMD) on atrial fibrillation (AF). - The digital twin accurately predicted the effectiveness of amiodarone in maintaining sinus rhythm in patients post-AF ablation, identifying those likely to benefit from the drug. - Virtual amiodarone tests using the digital twin platform showed dose-dependent electrophysiological changes, offering insights into optimal drug concentrations. - This technology may help personalize treatment strategies for atrial fibrillation, reducing recurrence rates and improving patient outcomes.
• Zanidatamab with mFOLFOX6-2, with or without bevacizumab, demonstrated significant antitumor activity in first-line HER2-positive metastatic colorectal cancer (mCRC). • The confirmed overall response rate (cORR) reached 90.9% across both treatment arms, with a 100% disease control rate, indicating substantial clinical benefit. • The combination therapy presented a manageable safety profile, with no treatment-related deaths and no discontinuations due to treatment-related adverse events (TRAEs). • These findings support zanidatamab-based combinations as a potential first-line treatment option for patients with HER2-positive mCRC.
